Opus Point Partners Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-93,805
Closed -$5.37M 48
2018
Q2
$5.37M Sell
93,805
-93,805
-50% -$5.11M 11.64% 2
2018
Q1
$10.3M Buy
187,610
+57,110
+44% +$3.42M 20.26% 1
2017
Q4
$7.32M Hold
130,500
6.33% 2
2017
Q3
$7.99M Hold
130,500
7.17% 1
2017
Q2
$6.97M Buy
130,500
+45,500
+54% +$2.22M 6.38% 1
2017
Q1
$4.1M Hold
85,000
3.04% 11
2016
Q4
$3.39M Hold
85,000
2.7% 11
2016
Q3
$4.12M Buy
+85,000
New +$4.04M 2.31% 6
2016
Q2
Sell
-64,462
Closed -$2.63M 45
2016
Q1
$2.63M Buy
64,462
+49,543
+332% +$2.19M 2.04% 22
2015
Q4
$1.07M Sell
14,919
-17,798
-54% -$1.19M 0.7% 39
2015
Q3
$1.91M Sell
32,717
-20,851
-39% -$1.78M 1.05% 26
2015
Q2
$4.84M Buy
53,568
+18,000
+51% +$1.55M 3.83% 4
2015
Q1
$2.82M Sell
35,568
-40,800
-53% -$3.03M 2.36% 24
2014
Q4
$4.79M Buy
+76,368
New +$4.48M 4.74% 1

Other funds holding BIB

Opus Point Partners Management's BIB Position: Q3 2018 in Review

Opus Point Partners Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2018, closing a stake of 93,805 shares — an estimated $5.37M sold.

Opus Point Partners Management first reported a position in BIB in Q4 2014 and held it in 14 quarters. The position peaked at $10.3M in Q1 2018. 41 funds tracked by Wall St. Rank hold BIB as of Q3 2018.

  • Opus Point Partners Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Opus Point Partners Management sold 93,805 ProShares Ultra NASDAQ Biotechnology shares in Q3 2018, an estimated $5.37M.
  • Opus Point Partners Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 14 quarters.
  • Opus Point Partners Management's ProShares Ultra NASDAQ Biotechnology position peaked at $10.3M in Q1 2018.
  • 41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.